Congress tradeDisclosed 9 days after the transaction; reported as an official range, not an exact amount.
Loading…
Amgen
AMGN · NASDAQ · Biotechnology
AMGN · NASDAQ · Biotechnology
Biotechnology company based in Thousand Oaks, California.
Last close, Oct 1, 2026
$407.27
Adjusted for splits and dividends
Last 12 months
+36.4%
S&P 500 +14.3% over the same dates
Market value
$220B
Last close × shares outstanding
Bets against the stock: 14.1M shares sold short (2.6% of shares outstanding), +8.4% vs the previous count, 4.9 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
6 sales
$4.11M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$36.8B
+10.0% vs the year before
Net income, fiscal 2025
$7.71B
As reported in the annual filing
Shares outstanding
541M
As of Jul 30, 2026
In fiscal 2025 the company spent $5.12B on dividends. Cash actually paid, from its cash-flow statement.
Disclosed 9 days after the transaction; reported as an official range, not an exact amount.
2 different filers disclosed AMGN within 90 days. Disclosed 10 days after the transaction; reported as an official range, not an exact amount.
2 different filers disclosed AMGN within 90 days. Disclosed 10 days after the transaction; reported as an official range, not an exact amount.
Congress tradeSits on Senate Finance, Health Care2 different filers disclosed AMGN within 90 days. Disclosed 21 days after the transaction; reported as an official range, not an exact amount.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 54.6% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 56.0%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 3,740 shares (about $1.62M) were not delivered on time for settlement on Aug 31, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
1 approval or clearance and 5 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
Notice · Food and Drug Administration
Fiduciary Duties in Selecting Designated Investment Alternatives
Proposed rule · Employee Benefits Security Administration
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice · Federal Trade Commission
Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
181 certified in FY2026 Q3, vs 213 a year earlier. 181 positions in total, median offered wage $140K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 40.5M shares
Capital World Investors
Schedule 13G: passive · filed May 14, 2026 · 29.6M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $298.50 on Oct 1, 2025 to $407.27 on Oct 1, 2026 (+36.4%). Disclosed trades in the last 12 months: 0 insider purchases, 14 insider sales (12 under pre-arranged plans), 5 Congress purchases, 9 Congress sales.
Top officer leaving
“Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
1 insider sold ~$400K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.